Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

CytRx Corp. (CYTR) Featured On Forbes.com For Aldoxorubicin's Potential As Treatment For Brain Cancer

|Includes: CytRx Corporation (CYTR)

In a recent review published on Forbes.com, contributor Tom Meyer highlights four biotech companies focused on advancing treatments for glioblastoma multiforme (GBM), listing CytRx Corp. alongside ImmunoCellular Therapeutics (NYSEMKT:IMUC), Northwest Biotherapeutics (NASDAQ:NWBO), and Celldex Therapeutics (NASDAQ:CLDX).

To read the full article visit: www.forbes.com/sites/tommeyer/2013/12/27.../

GBM is the most aggressive malignant brain tumor in humans. Current treatment includes chemotherapy, radiation, and surgery, though median survival even with these extremes is only 15 months.

Investors for a season had high expectations that ImmunoCellular Therapeutics and Northwest Biotherapeutics would lead the pack in developing an effective treatment for GBM, but as Meyer explains in the article, both companies fell short of this achievement.

"They were among the first to get into the field and have made significant progress. Unfortunately, for ImmunoCellular, that dream came crashing down earlier this month. On December 11th, the company reported that their Phase II trial did not reach statistical significance in the primary outcome of overall survival. This was a serious blow to both investors and the medical community as many had been hoping that the company would file for accelerated approval if the results were extremely favorable. Shares of the company collapsed after the announcement and traded as low $0.65. … Unfortunately, it appears that Northwest Biotherapeutics may soon take an ill-fated journey to the land of failed trials."

Alternately, Meyer discusses his bullish stance on CytRx, a biopharmaceutical R&D company focused on the clinical development of aldoxorubicin, the company's improved version of widely used and highly toxic chemotherapeutic agent, doxorubicin.

CytRx recently reported positive data from its phase 2b trial in patients with soft tissue sarcomas, demonstrating aldoxorubicin's superiority over doxorubicin in progression-free survival. The company in November said it was initiating a phase 2 clinical trial of aldoxorubicin in patients with GBM.

"Given the remarkable results that aldoxorubicin demonstrated in 1st-Line STS, it's hard not to believe that something similar could be in store for the Phase 2 GBM trial. CytRx certainly appears poised for a significant run in the months and years ahead as the company's platform continues to be validated by science."

Meyer further emphasizes his outlook on CytRx, detailing the company's strong cash balance, which is expected to fund operating expenses through 2015.

Celldex Therapeutics also gets a positive review for its brain cancer candidate rindopepimut, which is currently being evaluated in a phase 3 ACT IV study for newly diagnosed GBM, as well as in a phase 2 ReACT study in recurrent GBM.

Taking each company's performance and potential into consideration, Meyer surmises that:

"Investors looking to allocate capital to a promising company in the brain cancer space should consider CytRx Corporation and Celldex Therapeutics. Both companies appear to be developing unique, innovative approaches for tackling a complex and deadly disease. On the flip side, investors should probably stay away from both ImmunoCellular Therapeutics and Northwest Biotherapeutics, both of whom appear to be pursuing a science that hasn't quite proven itself."

For more information, visit cytrx.com

MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com